Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. developed cell therapies and immunotherapies for cancer and other incurable diseases, with company news centered on anitocabtagene autoleucel, or anito-cel, an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Coverage included clinical data from the iMMagine program, scientific presentations on the D-Domain binder, and collaboration activity with Kite, a Gilead company.
Arcellx became a wholly owned subsidiary of Gilead Sciences after the completed acquisition in 2026, and its common stock was delisted from the Nasdaq Global Select Market. Later company developments therefore include the completed transaction, shareholder-related deal coverage, capital-structure matters, and public-company status changes.
Arcellx and Kite, in partnership with Gilead Company, announced updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program. The global Phase 3 trial, iMMagine-3, will evaluate anito-cel in patients with relapsed and/or refractory multiple myeloma exposed to specific previous treatments. The technical transfer for manufacturing anito-cel is complete, and preliminary data from the iMMagine-1 trial is expected by year-end.
Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.
Arcellx, Inc. (NASDAQ: ACLX) reported financial highlights for Q1 2024, with $691.0 million in cash, collaboration revenue of $39.3 million, R&D expenses down by $0.6 million, G&A expenses up by $7.3 million, and a net loss of $7.2 million.
Arcellx, a biotechnology company focused on innovative immunotherapies for cancer, will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 and TD Cowen 5th Annual Oncology Innovation Summit. The company aims to enhance its investor relations through these engagements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.